Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720319 | 0.82 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL1720465 | 0.79 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DBCL6 | |
| SCHEMBL3327174 | 0.76 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1719903 | 0.75 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DNPSR1 | |
| SCHEMBL1719680 | 0.75 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1719398 | 0.74 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL3326728 | 0.72 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3326716 | 0.72 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6397973 | 0.70 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL29824397 | 0.70 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819708-B1 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-7648988-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-01-19 | — | — | US | disclosed |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | DOLLINGER HORST | 2008-06-26 | — | — | US | disclosed |
| EP-1819708-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058868-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | PDE4A 1428/4885PDE4B 1709/4885PDE4C 1814/4885 |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | PDE4A 1428/4885PDE4B 1709/4885PDE4C 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.